Quick Answer
Adaptive Biotechnologies Corp reported Revenue From Contract With Customer Excluding Assessed Tax of $276.98 million for the year ending 2025.
- Adaptive Biotechnologies Corp showed an increase of +54.8% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Adaptive Biotechnologies Corp's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Adaptive Biotechnologies Corp's Revenue From Contract With Customer Excluding Assessed Tax has grown by 620.4%.
- Historical annual values: Fiscal year 2025: $276.98 million | Fiscal year 2024: $178.96 million | Fiscal year 2023: $170.28 million | Fiscal year 2022: $185.31 million | Fiscal year 2021: $154.34 million | Fiscal year 2020: $98.38 million | Fiscal year 2019: $85.07 million | Fiscal year 2018: $55.66 million | Fiscal year 2017: $38.45 million.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: